Lir is an AI viral vector company. Our approach is to revolutionise gene therapy by tackling dose reduction, tissue targeting and immune evasion all at once through state-of-the-art AI modelling and a lab-in-the-loop screening pipeline.
Using our nAAVigator® AI platform we’re engineering viral vectors for gene therapy, starting with AAV. Our goal is to completely resurface viral vectors, enabling therapies that would be otherwise impossible.
Killian Hanlon, PhD
Gene therapy expert with over a decade of expertise in AAV engineering, with over half a dozen patents in the AAV space. Former Harvard postdoc with experience working with small and large pharma
Hugh O'Brien, PhD
AI and machine learning researcher with advanced degrees from Imperial and Kings College London. Over decade of experience building software and AI models for biological endpoints.
© 2025 Copyright: Lir Therapeutics
